Clinical trials: Diabetic Oculopathy
Proliferative Diabetic Retinopathy
The Individually Marked Panretinal lasEr phoTokoagUlation for Proliferative Diabetic Retinopathy Study - DETECT
The purpose of this study is to determine the threshold level of proliferative diabetic retinopathy progression and regression after standard panretinal photocoagulation.
- Trial name
- IMPETUS-D (NCT02157350)
- Testing
- Panretinal laser photocoagulation
- Where
- Denmark
- Volunteers
- 65 people
- Sponsor
- Odense University Hospital
Diabetic Macular Edema (DME)
A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema
The purpose of this study is to learn about the effects of BGE-102 on change in vision in participants with center-involved diabetic macular edema (CI-DME).
- Trial name
- QUELL-DME (NCT07812090)
- Testing
- Oral BGE-102, Anti-VEGF
- Where
- 16 sites in United States
- Volunteers
- 180 people
- Sponsor
- BioAge Labs, Inc.
Vitreous Hemorrhage, Diabetic Retinopathy
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage
The purpose of this study is to determine if intravitreal injection of Vitrase (ovine hyaluronidase) clears vitreous hemorrhage
- Trial name
- NCT00198497
- Testing
- Vitrase
- Where
- 58 sites in Australia, Brazil and 7 more
- Volunteers
- 510 people
- Sponsor
- Bausch & Lomb Incorporated
Diabetic Retinopathy
Comparison of Different Fluence Settings for Yellow Subthreshold Laser Treatment in Diabetic Macular Edema
To assess the safety and efficacy of two subthreshold parameters (5% and 15% duty cycle (DC)) compared to standard ETDRS (early treatment of diabetic retinopathy study) continuous wave (CW) laser
- Trial name
- NCT03571659
- Testing
- Laser
- Volunteers
- 32 people
- Sponsor
- L.V. Prasad Eye Institute
Diabetic Retinopathy, Diabetic Cataract
Pars Plana Vitrectomy Combined With Phacoemulsification Cataract Surgery in Phakic Diabetes Retinopathy Patients
Pars plana vitrectomy (PPV) is one of the most widely used surgical therapies to proliferative diabetic retinopathy in the world.
- Trial name
- NCT04729023
- Testing
- Pars plana vitrectomy combined with cataract surgery., Pars plana vitrectomy with subsequent cataract surgery.
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Diabetic Retinopathy
Self-testing Diagnosis Imaging Model for Diabetic Retinopathy
This is a prospective clinical study. At the Shaoguan Diabetic Eye Screening Programme, patients ages 30-80 will undergo the two diagnostic models: (1) in a remote diagnostic clinic site, patients undergo a self-testing device…
- Trial name
- NCT05223556
- Testing
- Full Self-Diagnostic device in a remote diagnostic imaging site, Human imager operated diagnostic device in the hospital
- Where
- China
- Volunteers
- 167 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy New Vessels on Disc
The Effect of Combination of Vitamin A, Vitamin E, Sodium Hyaluronate 0.15% Eye Drop Compared With Sodium Hyaluronate 0.1% Eye Drop to Tear Film Stability and Conjunctival Goblet Cells Density in Patient With Non-Proliferative Diabetic Retinopathy (NPDR), and Proliferative Diabetic Retinopathy (PDR)
Commonly know that one of the complications caused by Diabetes Mellitus (DM) is microangiopathy. Microangiopathy in the long term may lead to neuropathy of the corneal nerves.
- Conditions
- Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy New Vessels on Disc, Dry Eye Syndromes
- Trial name
- NCT04000789
- Testing
- Sodium Hyaluronate, Vitamin A, Vitamin E
- Volunteers
- 96 people
- Sponsor
- Dr Cipto Mangunkusumo General Hospital
Diabetic Retinopathy
HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia
This is a study in people with a type of diabetic eye disease called diabetic retinopathy with diabetic macular ischemia. People who have had laser treatment for their diabetic retinopathy can participate in the study.
- Trial name
- HORNBILL (NCT04424290)
- Testing
- BI 764524
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Diabetic Macular Edema, Diabetic Retinopathy
Reading Center - Occurence of Diabetic Macular Edema in Patients With Diabetes Mellitus in Slovak Republic
The aim of the study is to find out prevalence of diabetic macular edema (DME) in patients with diabetes mellitus in Slovak Republic.The outcome of the project will be epidemiology survey, prevalence of wet form of Diabetic…
- Trial name
- NCT02063321
- Volunteers
- 762 people
- Sponsor
- Emil Martinka
Diabetes Mellitus, Obstructive Sleep Apnea
Role of Obstructive Sleep Apnea Syndrome in the Occurrence of Diabetic Retinopathy in Type 2 Diabetes.
Diabetic retinopathy (DR) is the most common visual complication of diabetes. Risk factors for developing DR are diabetes duration, glycemic control, and hypertension .
- Trial name
- NCT03314467
- Testing
- polysomnography
- Where
- Belgium
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Diabetes Mellitus, Type 2, Diabetic Retinopathy
Exploring the Effectiveness of AI Generative Models for Diabetic Patients
We plan to explore the usability of Generative AI-Chatbot for Diabetic Patient
- Conditions
- Diabetes Mellitus, Type 2, Diabetic Retinopathy, Diabetes
- Trial name
- NCT05883072
- Testing
- Exploring AI-Chatbot
- Where
- Pakistan
- Volunteers
- 300 people
- Sponsor
- Pakistan Council of Scientific and Industrial Research
Diabetic Retinopathy
Serum and Intraocular Levels of Erythropoietin and VEGF in Type 2 Diabetes Patients With Proliferative Retinopathy
Some studies have recently shown that the concentration of erythropoietin in the vitreous humor of diabetic patients suffering from diabetic retinopathy is higher than non-diabetic patients.
- Trial name
- UVA-EVA (NCT01871207)
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- Università degli Studi di Brescia
Diabetes Mellitus, Diabetic Retinopathy
A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema
Part A of the study is conducted to select the THR-149 dose level. Part B of the study is conducted to assess the efficacy and safety of the selected dose level compared to aflibercept, up to Month 3.
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- KALAHARI (NCT04527107)
- Testing
- THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3
- Where
- 78 sites in United States, Czechia and 6 more
- Volunteers
- 135 people
- Sponsor
- Oxurion
Diabetic Retinopathy
A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
The purpose of this study is to determine the safety and efficacy of Vitreosolve® in diabetic retinopathy patients.
- Trial name
- NCT00908778
- Testing
- Vitreosolve
- Where
- 5 sites in India, Mexico
- Volunteers
- 160 people
- Sponsor
- Vitreoretinal Technologies, Inc.
Diabetic Retinopathy
The Diabetic Retinopathy Screening, Prevention and Control Program
The greatest harm of diabetes is various acute and chronic complications, especially diabetic retinopathy(DR), leading to extremely high rates of disability and blindness.
- Trial name
- NCT04240652
- Where
- 2 sites in China
- Volunteers
- 500,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Age-related Macular Degeneration, Central Retinal Vein Occlusion
Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival
Since 2004, intravitreal injection of Avastin, Lucentis, and Macugen for wet age-related macular degeneration, retinal vein occlusion, and diabetic macular edema are being administered in the United States at increasing rates.
- Conditions
- Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT01640171
- Testing
- Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Retina Vitreous Associates of Florida
Diabetes Complications, Diabetic Retinopathy
Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy
This study proposes to carefully examine the hypothesis that human inducible pluripotent stem cells (iPSCs) can be effectively employed as a future therapeutic option for individuals with diabetic retinopathy and macular…
- Trial name
- iPSC (NCT03403699)
- Testing
- Generation of inducible pluripotent stem cells
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Retinopathy, Diabetic
Evaluation of a Health Education Program for Type 2 Diabetes Patients
The goal of this, Retrospective and Prospective Low- Interventional study, is to implement health education interventions to promote self-care and reduce disease complications in DM Type 2 patients at higher risk of…
- Trial name
- EDUCA-DM (NCT06066021)
- Testing
- health educational sessions in diabetic patients type 2.
- Where
- Portugal
- Volunteers
- 27 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Diabetic Macular Edema (DME)
Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with diabetic macular edema (DME).
- Trial name
- GOBI (NCT07842016)
- Testing
- OLN324, Aflibercept
- Volunteers
- 450 people
- Sponsor
- Ollin Biosciences, Inc.
Diabetic Macular Edema (DME)
Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
This study is an open-label, dose-escalating, 48-week study assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or 0.5 mg AXT107 in approximately 18…
- Trial name
- CONGO (NCT04697758)
- Testing
- AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg
- Where
- 10 sites in United States
- Volunteers
- 6 people
- Sponsor
- AsclepiX Therapeutics, Inc.